244 related articles for article (PubMed ID: 16301117)
1. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Jaggi M; Johansson SL; Baker JJ; Smith LM; Galich A; Balaji KC
Urol Oncol; 2005; 23(6):402-6. PubMed ID: 16301117
[TBL] [Abstract][Full Text] [Related]
2. N-cadherin switching occurs in high Gleason grade prostate cancer.
Jaggi M; Nazemi T; Abrahams NA; Baker JJ; Galich A; Smith LM; Balaji KC
Prostate; 2006 Feb; 66(2):193-9. PubMed ID: 16173043
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
4. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
Saha B; Arase A; Imam SS; Tsao-Wei D; Naritoku WY; Groshen S; Jones LW; Imam SA
Prostate; 2008 Jan; 68(1):78-84. PubMed ID: 18008331
[TBL] [Abstract][Full Text] [Related]
6. Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers.
Aust DE; Terdiman JP; Willenbucher RF; Chew K; Ferrell L; Florendo C; Molinaro-Clark A; Baretton GB; Löhrs U; Waldman FM
Mod Pathol; 2001 Jan; 14(1):29-39. PubMed ID: 11211307
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression.
Shih HC; Shiozawa T; Miyamoto T; Kashima H; Feng YZ; Kurai M; Konishi I
Anticancer Res; 2004; 24(6):3843-50. PubMed ID: 15736420
[TBL] [Abstract][Full Text] [Related]
8. [Expressions of E-cadherin and beta-catenin in LNCaP and ARCaP cell lines and their significance].
Jiang YG; Zhao JH; Luo Y; He DL; Li N; Cui XH; Peng T
Zhonghua Nan Ke Xue; 2009 Oct; 15(10):867-71. PubMed ID: 20112731
[TBL] [Abstract][Full Text] [Related]
9. Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland.
Lazari P; Poulias H; Gakiopoulou H; Thomopoulou GH; Barbatis C; Lazaris AC
Urol Int; 2013; 90(1):109-16. PubMed ID: 23220849
[TBL] [Abstract][Full Text] [Related]
10. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis.
Chen S; Liu J; Li G; Mo F; Xu X; Zhang T; Zhang X; Li J; Han X; Sun Y
Scand J Gastroenterol; 2008; 43(4):456-64. PubMed ID: 18365911
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced beta-catenin-Tcf/Lef-dependent transcription.
Torres VA; Tapia JC; Rodriguez DA; Lladser A; Arredondo C; Leyton L; Quest AF
Mol Cell Biol; 2007 Nov; 27(21):7703-17. PubMed ID: 17785436
[TBL] [Abstract][Full Text] [Related]
12. [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis].
Tang XJ; Zhou QH; Zhang SF; Liu LX
Ai Zheng; 2005 May; 24(5):616-21. PubMed ID: 15890109
[TBL] [Abstract][Full Text] [Related]
13. Frequent occurrence of abnormal E-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis.
Hirata K; Ajiki T; Okazaki T; Horiuchi H; Fujita T; Kuroda Y
Oncology; 2006; 71(1-2):102-10. PubMed ID: 17341890
[TBL] [Abstract][Full Text] [Related]
14. [Leukemia cell surface expression of E-cadherin and its correlation with membrane localization of beta-catenin].
Rao Q; Xu ZF; Wang JY; Meng JH; Tang KJ; Tian Z; Xing HY; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):592-4. PubMed ID: 19175984
[TBL] [Abstract][Full Text] [Related]
15. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
[TBL] [Abstract][Full Text] [Related]
16. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas.
Kim MJ; Jang SJ; Yu E
Hum Pathol; 2008 Feb; 39(2):251-8. PubMed ID: 17959228
[TBL] [Abstract][Full Text] [Related]
17. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
Chetty R; Serra S; Asa SL
Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
[TBL] [Abstract][Full Text] [Related]
18. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.
Contreras HR; Ledezma RA; Vergara J; Cifuentes F; Barra C; Cabello P; Gallegos I; Morales B; Huidobro C; Castellón EA
Urol Oncol; 2010; 28(5):534-40. PubMed ID: 19450993
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion.
Morita N; Uemura H; Tsumatani K; Cho M; Hirao Y; Okajima E; Konishi N; Hiasa Y
Br J Cancer; 1999 Apr; 79(11-12):1879-83. PubMed ID: 10206308
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
